CDMO Intertek has announced an expansion of a GMP stability storage facility near Cambridge, UK, noting that the expanded facility offers custom temperature and relative humidity conditions and is suitable for stability testing of a wide range of formulations, including biologics. The announcement also notes the facility’s suitability for certain inhalation products, specifically citing plastic nebules used for inhalation formulations.
The stability storage facility expansion follows several other recent expansions that the company has attributed to increasing demand. In May 2025, Intertek announced the addition of laboratory space at its Melbourn site for characterization of large molecules for inhalation. In December of that year, the company said that it had acquired a new facility in Melbourn that would provide additional GMP manufacturing capacity, citing “rising client demand for expert support in the inhaled biologics space.”
Intertek President, Global Pharmaceutical Services, Olivier Coppey commented, “This expansion cements our Royston facility as one of Europe’s largest and most advanced GMP pharmaceutical stability storage sites. Combined with our teams’ outstanding expertise in analytical and formulation support, we help our clients mitigate risk and keep their challenging pharmaceutical development programs on track.”
Director of Pharmaceutical Development and Manufacture Teresa Iley said, “By offering pioneering standard and bespoke stability storage programs, fully integrated with expert formulation development and specialized analytical capabilities such as GMP-compliant combination drug product testing, our customers gain deeper product insight and stronger regulatory readiness. We continuously expand our GMP expertise to ensure precise characterization of purity, potency, identity and stability, supporting faster development of next-generation drug–device combination therapies.”
Read the Intertek press release
